Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Lexeo Therapeutics (LXEO) Change in Account Payables (2022 - 2026)

Lexeo Therapeutics' Change in Account Payables history spans 2 years, with the latest figure at $394000.0 for Q4 2023.

On a quarterly basis, Change in Account Payables rose 132.27% to $394000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was -$180000.0, a N/A change, with the full-year FY2025 number at -$1.6 million, down 165.64% from a year prior.
Change in Account Payables hit $394000.0 in Q4 2023 for Lexeo Therapeutics, up from $290000.0 in the prior quarter.
Over the last five years, Change in Account Payables for LXEO hit a ceiling of $1.0 million in Q1 2023 and a floor of -$1.9 million in Q2 2023.